Nasdaq

Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials

Phase 2 study to confirm dose to be initiated in near term, with planned interim analysis through 3 months; Phase 3 study planning is underway CMV is the most common infectious cause of birth defects ...
Nasdaq

Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of ...
FiercePharma

VBI Vaccines touts positive phase 1 data for CMV vaccine

VBI wants to prevent cytomegalovirus infections in newborns by vaccinating women before pregnancy, a market it says carries blockbuster potential. As the biotech works down the development path, it ...
Hosted on MSN

Evaxion Reports Positive Data for CMV Vaccine Program

Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...